Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Daniel Rosenthal

Internal Medicine Skokie, IL Medical Doctor

NPI 1023120599 CMS profile 91509

9933 Lawler Ave, Ste 227, Skokie, IL 60077

Open in the dashboard

General payments

$6,522

378 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Daniel Rosenthal of Skokie, IL is reported in the CMS Open Payments database as having received $6,522 across 378 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $523 26
2022 General $1,811 94
2021 General $1,821 106
2020 General $1,003 68
2019 General $1,364 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Rosenthal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Daniel Rosenthal were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Daniel Rosenthal Internal Medicine median Middle half National median
2019 $1,364 $159 $48–$570 $163
2020 $1,003 $119 $33–$402 $114
2021 $1,821 $135 $37–$521 $132
2022 $1,811 $141 $42–$496 $149
2023 $523 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AbbVie, Inc. $1,054 56 payments
  2. Novo Nordisk Inc $761 50 payments
  3. Janssen Pharmaceuticals, Inc $628 38 payments
  4. Pfizer Inc. $518 30 payments
  5. AstraZeneca Pharmaceuticals LP $517 30 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $413 28 payments
  7. Allergan Inc. $360 33 payments
  8. Preventric Diagnostics, Inc. $260 2 payments
  9. Lilly USA, LLC $260 17 payments
  10. Amgen Inc. $191 9 payments
  11. Other $1,560 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,522 378 payments
Products named General payments · program years 2019–2023
  1. VRAYLAR Neuroscience $1,017 53 payments
  2. Ozempic $650 42 payments
  3. RYBELSUS $536 36 payments
  4. XARELTO $526 33 payments
  5. ELIQUIS $390 22 payments
  6. FARXIGA $290 16 payments
  7. TRINTELLIX $264 17 payments
  8. VRAYLAR Neuroscience $262 23 payments
  9. BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM $260 2 payments
  10. SYMBICORT $220 11 payments
  11. Other $4,029 231 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

3,014

Median for Psychiatry: 574

Drug cost

$102,589

Median for Psychiatry: $27,624

Branded share of claims

20.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Topamax Topiramate Brand 12 $14,277
Divalproex Sodium Er Divalproex Sodium Brand 80 $6,928
Ziprasidone Hcl Generic 29 $5,658
Aripiprazole Generic 41 $4,734
Paliperidone Er Paliperidone Brand 11 $4,537
Clozapine Generic 77 $4,116
Chlorpromazine Hcl Generic 27 $3,936
Clomipramine Hcl Generic 13 $3,441
Methylphenidate Er Methylphenidate Hcl Brand 44 $3,239
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 98 $3,182

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$111,197

Medicare's payments for the services billed

Medicare patients

122

Average age 69

Services billed

1,504

75 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 62%
High blood pressure 51%
Arthritis 45%
Diabetes 23%
Ischemic heart disease 20%
Chronic kidney disease 20%
Osteoporosis 20%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

378 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record